Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial
Authors:
- Anne B ChangAnne B Chang
- Keith GrimwoodKGKeith Grimwood
- Colin F RobertsonCRColin F Robertson
- Andrew C WilsonAWAndrew C Wilson
- Peter P van AsperenPAPeter P van Asperen
- Kerry-Ann F O’gradyKOKerry-Ann F O’grady
- Theo P SlootsTSTheo P Sloots
- Paul J TorzilloPTPaul J Torzillo
- Emily J BaileyEBEmily J Bailey
- Gabrielle B McCallumGMGabrielle B McCallum
- Ian B MastersIMIan B Masters
- Catherine A ByrnesCBCatherine A Byrnes
Open Access
- 31 August 2012
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 13 (1) , 156
Abstract
Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis exacerbations, but not all practitioners agree. Inadequately treated exacerbations may risk lung function deterioration. Our study tests the hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of respiratory exacerbations by day 14 in children with bronchiectasis unrelated to cystic fibrosis. We are conducting a b ronchiectasis e xacerbation st udy (BEST), which is a multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel group trial, in five centres (Brisbane, Perth, Darwin, Melbourne, Auckland). In the component of BEST presented here, 189 children fulfilling inclusion criteria are randomised (allocation-concealed) to receive amoxicillin-clavulanic acid (22.5 mg/kg twice daily) with placebo-azithromycin; azithromycin (5 mg/kg daily) with placebo-amoxicillin-clavulanic acid; or placebo-azithromycin with placebo-amoxicillin-clavulanic acid for 14 days. Clinical data and a paediatric cough-specific quality of life score are obtained at baseline, at the start and resolution of exacerbations, and at day 14. In most children, blood and deep nasal swabs are also collected at the same time points. The primary outcome is the proportion of children whose exacerbations have resolved at day 14. The main secondary outcome is the paediatric cough-specific quality of life score. Other outcomes are time to next exacerbation; requirement for hospitalisation; duration of exacerbation; and spirometry data. Descriptive viral and bacteriological data from nasal samples and blood markers will also be reported. Effective, evidence-based management of exacerbations in people with bronchiectasis is clinically important. Yet, there are few randomised controlled trials (RCTs) in the neglected area of non-cystic fibrosis bronchiectasis. Indeed, no published RCTs addressing the treatment of bronchiectasis exacerbations in children exist. Our multicentre, double-blind RCT is designed to determine if azithromycin and amoxicillin-clavulanic acid, compared with placebo, improve symptom resolution on day 14 in children with acute respiratory exacerbations. Our planned assessment of the predictors of antibiotic response, the role of antibiotic-resistant respiratory pathogens, and whether early treatment with antibiotics affects duration and time to the next exacerbation, are also all novel. Australia and New Zealand Clinical Trials Register (ANZCTR) number ACTRN12612000011886.Keywords
This publication has 67 references indexed in Scilit:
- Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocolTrials, 2011
- Respiratory Bacterial Pathogens in the Nasopharynx and Lower Airways of Australian Indigenous Children with BronchiectasisThe Journal of Pediatrics, 2010
- Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluationTrials, 2010
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- Qualitative Analysis of High-Resolution CT Scans in Severe AsthmaChest, 2009
- Asthma and protracted bronchitis: Who fares better during an acute respiratory infection?Journal of Paediatrics and Child Health, 2009
- Distinguishing Molecular Features and Clinical Characteristics of a Putative New Rhinovirus Species, Human Rhinovirus C (HRV C)PLOS ONE, 2008
- Outcomes in children treated for persistent bacterial bronchitisThorax, 2007
- Prevalence and Economic Burden of BronchiectasisClinical Pulmonary Medicine, 2005
- Streptococcus pneumoniae and Noncapsular Haemophilus influenzae Nasal Carriage and Hand Contamination in ChildrenThe Pediatric Infectious Disease Journal, 2005